Is chronic kidney disease-mineral bone disorder (CKD-MBD) really a syndrome?

Nephrology Dialysis Transplantation

Volumn 29, Issue 10, 2014, Pages 1815-1820

  Cozzolino, Mario ^a   Ureña Torres, Pablo ^b   Vervloet, Marc G ^c   Brandenburg, Vincent ^d   Bover, Jordi ^e   Goldsmith, David ^f   Larsson, Tobias E ^g,h   Massy, Ziad A ^i,j   Mazzaferro, Sandro ^k  

^a UNIVERSITY OF MILAN   (Italy)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^e FUNDACIÓ PUIGVERT   (Spain)

^f KING'S COLLEGE LONDON   (United Kingdom)

^g KAROLINSKA INSTITUTE   (Sweden)

^h KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

ⁱ LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^j UNIVERSITÉ DE PICARDIE JULES VERNE   (France)

^k SAPIENZA UNIVERSITY OF ROME   (Italy)

more..

Author keywords

cardiovascular outcome; chronic kidney disease; parathyroid hormone; renal osteodystrophy; syndrome

Indexed keywords

CREATININE; PHOSPHATE BINDING AGENT; SERUM ALBUMIN;

ALBUMINURIA; BLOOD VESSEL CALCIFICATION; BONE DISEASE; BONE METABOLISM; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CHRONIC KIDNEY DISEASE MINERAL BONE DISORDER; CREATININE BLOOD LEVEL; END STAGE RENAL DISEASE; GLOMERULUS FILTRATION RATE; HEMODIALYSIS; HUMAN; HYPERPHOSPHATEMIA; MINERAL METABOLISM; NEPHROTIC SYNDROME; PRIORITY JOURNAL; PROGNOSIS; RENAL OSTEODYSTROPHY; REVIEW; SCORING SYSTEM; SECONDARY HYPERPARATHYROIDISM; UREMIA; BONE DENSITY; CALCINOSIS; CHRONIC KIDNEY FAILURE; METABOLIC BONE DISEASE; METABOLISM; PATHOLOGY; SYNDROME;

BONE DENSITY; BONE DISEASES, METABOLIC; CALCINOSIS; HUMANS; HYPERPHOSPHATEMIA; RENAL INSUFFICIENCY, CHRONIC; SYNDROME;

EID: 84915774013     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gft514     Document Type: Review

References (24)

1. Go AS, Chertow GM, Fan D et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-1305
2. Shlipak MG, Matsushita K, Ärnlöv J et al. Prognosis Consortium. Cystatin C versus creatinine in determining risk based on kidney function. N Engl J Med 2013; 369: 932-943
3. KDIGO Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl 2013; 3: 8
4. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002; 287: 356-359
5. Kahn R, Buse J, Ferrannini E et al. The metabolic syndrome: time for a critical appraisal. Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2005; 28: 2289-2304
6. Grundy SM. Does a diagnosis of metabolic syndrome have value in clinical practice? Am J Clin Nutr 2006; 83: 1248-1251
7. Moe S, Drüeke T, Cunningham J et al. Kidney Disease: Improving Global Outcomes (KDIGO). Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2006; 69: 1945-1953
8. London GM. Bone-vascular axis in chronic kidney disease: a reality? Clin J Am Soc Nephrol 2009; 4: 254-257
9. Thompson B, Towler DA. Arterial calcification and bone physiology: role of the bone-vascular axis. Nat Rev Endocrinol 2012; 8: 529-543.
10. Tentori F, Blayney MJ, Albert JM et al. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2008; 52: 519-530
11. Floege J, Kim J, Ireland E et al. on behalf of the ARO Investigators. Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population. Nephrol Dial Transplant 2011; 26: 1948-1955
12. Naves-Díaz M, Passlick-Deetjen J, Guinsburg A et al. Calcium, phosphorus, PTH and death rates in a large sample of dialysis patients from Latin America. The CORES Study. Nephrol Dial Transplant 2011; 26: 1938-1947
13. Martin KJ, González EA. Prevention and control of phosphate retention/ hyperphosphatemia in CKD-MBD: what is normal, when to start, and how to treat? Clin J Am Soc Nephrol 2011; 6: 440-446
14. Isakova T, Gutiérrez OM, Chang Y et al. Phosphorus binders and survival on hemodialysis. J Am Soc Nephrol JASN 2009; 20: 388-396.
15. Lopes AA, Tong L, Thumma J et al. Phosphate binder use and mortality among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS): evaluation of possible confounding by nutritional status. Am J Kidney Dis 2012; 60: 90-101
16. Cozzolino M, Brancaccio D, Cannella G et al.; FARO Study Group. VDRA therapy is associated with improved survival in dialysis patients with serum intact PTH 150 pg/mL: results of the Italian FARO Survey. Nephrol Dial Transplant 2012; 27: 3588-3594
17. Jamal SA, Vandermeer B, Raggi P et al. Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis. Lancet 2013; 382: 1268-1277
18. Cannata-Andía JB, Fernández-Martín JL, Locatelli F et al. Use of phosphate-binding agents is associated with a lower risk of mortality. Kidney Int 2013; 84: 998-1008
19. EVOLVE Trial InvestigatorsChertow GM, Block GA, Correa-Rotter R et al. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med 2012; 367: 2482-2494
20. Zimmet P, Magliano D, Matsuzawa Y et al. The metabolic syndrome: a global public health problem and a new definition. J Atheroscler Thromb 2005; 12: 295-300
21. Uhlig K, Berns JS, Kestenbaum B et al. KDOQI US Commentary on the 2009 KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of CKD-Mineral and Bone Disorder (CKD-MBD). Am J Kidney Dis 2010; 55: 773-799
22. Manns BJ, Hodsman A, Zimmerman DL et al. Canadian Society of Nephrology Commentary on the 2009 KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of CKD-Mineral and Bone Disorder (CKD-MBD). Am J Kidney Dis 2010; 55: 800-812
23. Goldsmith D, Covic A, Fouque D et al. Endorsement of the Kidney Disease Improving Global Outcomes (KDIGO) Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guidelines: a European Renal Best Practice (ERBP) commentary statement. Nephrol Dial Transplant 2010; 25: 3823-3831
24. Cozzolino M, Mazzaferro S, Brandenburg V. The treatment of hyperphosphataemia in CKD: calcium-based or calcium-free phosphate binders? Nephrol Dial Transplant 2011; 26: 402-407